• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

    6/4/26 8:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email

    DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer.

    The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide.

    "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Cenly Chen, Chief Executive Officer of ChronoScale. "Raj and Lawrence bring exceptional experience building and operating some of the world's most advanced AI infrastructure platforms. Their leadership will strengthen our ability to innovate, scale efficiently, and deliver the infrastructure foundation our customers need to power the next generation of AI."

    Raj Jegannathan joins ChronoScale as Chief Technology Officer after an over thirteen-year tenure at Tesla, where he most recently served as Vice President and reported directly to Elon Musk. At Tesla, he led a broad portfolio spanning AI infrastructure, one of the world's largest GPU clusters, large-scale storage systems, global information security, and enterprise technology platforms.

    At ChronoScale, Mr. Jegannathan will lead Platforms, Engineering, Infrastructure, Enterprise AI, Data, IT, and Information Security. His focus will be on helping customers maximize the return on investment of AI deployments by bridging the gap between raw compute capacity and measurable business outcomes. His experience operating complex global systems across manufacturing, logistics, retail, workplace operations, and supply chain environments positions him to help scale ChronoScale's platform for enterprise customers worldwide.

    "The next wave of AI success will be determined by how effectively organizations translate infrastructure investments into real-world outcomes," said Jegannathan. "ChronoScale is uniquely positioned to help customers close that gap, and I look forward to building platforms that deliver measurable value at scale."

    Lawrence Lam joins ChronoScale as Chief Product Officer, where he will be responsible for setting the Company's global product vision, accelerating the go-to-market strategy for innovative offerings, and defining platform strategy supporting compute-as-a-service, tokenized factory, and other next-generation AI services. He will lead ChronoScale's accelerator compute, photonic networking, and low-latency AI storage platforms while overseeing product benchmarking, AI cloud infrastructure, and data center buildouts globally.

    Mr. Lam brings more than 20 years of experience building and scaling global cloud and AI platforms. He has contributed to more than $20 billion in AI infrastructure deployments worldwide, helping drive the success of Supermicro AI solutions focused on full-stack AI accelerators, low-latency storage, and advanced AI networking technologies. His leadership will support ChronoScale's continued expansion across North America, EMEA, and APAC markets, where demand for AI training, fine-tuning, and inference infrastructure continues to accelerate.

    "Enterprises are increasingly looking for integrated AI infrastructure solutions that combine compute, networking, storage, and operational excellence," said Lam. "ChronoScale has a unique opportunity to help customers accelerate AI adoption with purpose-built platforms designed for performance and scale. I'm excited to help shape that vision."

    The appointments come as demand for AI compute infrastructure continues to accelerate globally, creating increasing requirements for scalable, high-performance environments optimized for AI training, inference, and enterprise AI workloads.

    As previously announced, ChronoScale was formed through the strategic combination of Applied Digital's cloud business and EKSO Bionics Holdings, Inc., and now operates as an independent public company delivering scalable, GPU-based infrastructure optimized for AI training, inference, and high-performance computing.

    About ChronoScale

    ChronoScale (NASDAQ:CHRN) ChronoScale is an accelerated compute platform purpose-built to support demanding artificial intelligence workloads. Focused on large-scale deployments, the platform delivers dedicated compute environments optimized for performance, consistency, and long-term operational execution, with the ability to scale capacity alongside accelerating AI demand.

    Forward-Looking Statements

    Statements in this Press Release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but are not limited to, (i) statements regarding the Company, its plans and objectives and anticipated future economic performance; (ii) statements about the cloud compute industry; (iii) statements regarding the Company's ability to expand capacity and meet accelerating demand; (iv) statements regarding future leadership of the Company; and (v) statements of assumptions underlying other statements and statements about the Company or its business. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations. These risks, uncertainties, and other factors include: difficulties and delays in integrating the combined business resulting from the recently consummated business combination; the possibility that the anticipated benefits of the business combination are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies; limitations on the Company's ability to attract and retain key personnel, including executive officers and Board members of the Company; customer concentration, and an inability to renew existing customer agreements; the success of the Company's risk management activities, including any failure by the Company to implement and maintain effective internal controls; litigation, including the potential litigation concerning the business combination; cash flow and access to capital; conditions in the debt and equity capital markets; slower than anticipated growth in the cloud compute industry; uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the SEC on February 23, 2026, as amended on April 10, 2026, subsequently filed Quarterly Reports on Form 10-Q, the definitive Information Statement on Schedule 14C filed with the SEC on April 3, 2026, and the risks described in other filings that the Company may make from time to time with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required by applicable law.

    Investor Relations & Media Contacts

    Matt Glover or Ralf Esper

    Gateway Group, Inc.

    (949) 574-3860

    APLD@gateway-grp.com



    Primary Logo

    Get the next $EKSO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cummins Wes was granted 200,000 shares (SEC Form 4)

    4 - ChronoScale Corp (0001549084) (Issuer)

    5/18/26 6:00:28 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Director Miller Douglas S was granted 200,000 shares (SEC Form 4)

    4 - ChronoScale Corp (0001549084) (Issuer)

    5/18/26 6:00:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Director Benson Ella G. was granted 200,000 shares (SEC Form 4)

    4 - ChronoScale Corp (0001549084) (Issuer)

    5/18/26 6:00:27 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    SEC Filings

    View All

    Ekso Bionics Holdings Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - ChronoScale Corp (0001549084) (Filer)

    6/4/26 4:15:33 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Amendment: Ekso Bionics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - ChronoScale Corp (0001549084) (Filer)

    5/20/26 5:14:33 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SCHEDULE 13D filed by Ekso Bionics Holdings Inc.

    SCHEDULE 13D - ChronoScale Corp (0001549084) (Subject)

    5/12/26 8:30:02 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $11,520 worth of shares (1,200 units at $9.60) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/19/26 4:03:47 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $970,069 worth of shares (102,029 units at $9.51) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/17/26 3:42:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

    DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide. "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Ce

    6/4/26 8:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth

    DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vice President & Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. "We believe the mar

    5/6/26 8:00:00 AM ET
    $EKSO
    $SMCI
    Industrial Machinery/Components
    Industrials
    Computer Manufacturing
    Technology

    Ekso Bionics Prices $5.852 million Private Placement

    SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company's Series B Preferred Stock (the "Preferred Stock") and warrants (the "Warrants") to purchase up to an aggregate of 355,960 shares of common stock of the Company in a private placement transaction (the "Private Placement"). The shares of Preferred Stock will have a stated value of $1,000 per share and b

    1/21/26 8:30:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    View All

    ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

    DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide. "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Ce

    6/4/26 8:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth

    DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vice President & Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. "We believe the mar

    5/6/26 8:00:00 AM ET
    $EKSO
    $SMCI
    Industrial Machinery/Components
    Industrials
    Computer Manufacturing
    Technology

    Ekso Bionics Accepted into NVIDIA Connect Program

    Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

    5/15/25 7:45:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    11/14/24 3:29:01 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

    SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    2/11/22 6:17:59 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    2/12/21 10:16:25 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Financials

    Live finance-specific insights

    View All

    Ekso Bionics Reports Second Quarter 2025 Financial Results

    SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, supporting Ekso's new strategic initiative to build a proprietary foundation model for human motion and to help develop and integrate related new artificial intelligence

    7/28/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow

    SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at ww

    7/21/25 4:45:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics Reports First Quarter 2025 Financial Results

    SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

    5/5/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials